Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen

被引:11
|
作者
Aksoy, Evrim Kahramanoglu [1 ]
Sapmaz, Ferdane Pirincci [1 ]
Goktas, Zeynep [2 ]
Uzman, Metin [1 ]
Nazligul, Yasar [1 ]
机构
[1] Hacettepe Univ, Kecloren Training & Res Hosp, Dept Gastroenterol, Sanatoryum Caddesi Ardahan Sokak D 25, TR-06280 Ankara, Turkey
[2] Hacettepe Univ, Kecloren Training & Res Hosp, Dept Nutr & Dietet, Fac Hlth Sci, Ankara, Turkey
关键词
Helicobacter pylori infection; Bismuth-containing quadruple therapy; Levofloxacin-containing triple therapy; Eradication rate; RESCUE REGIMENS; EFFICACY; CLARITHROMYCIN; RESISTANCE; METAANALYSIS; INFECTION;
D O I
10.1159/000484930
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to compare the efficacy and safety of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth-containing quadruple therapy as a firstline regimen for the eradication of Helicobacter pylori. Methods: A total of 329 patients with H. pylori infection were randomly divided into 3 groups to receive one of the following regimens: (a) levofloxacin-containing bismuth quadruple therapy RBAL (rabeprazole 20 mg, b.i.d., bismuth subsalicylate 562 mg, b.i.d., amoxicillin 1 g, b.i.d, levofloxacin 500 mg, once daily), (b) standard bismuth quadruple therapy, RBMT (rabeprazole 20 mg, b.i.d, subsalicylate 562 mg, b.i.d., metronidazole 500 mg, t.i.d, tetracycline 500 mg, q.i.d), or (c) levo-floxacin-containing triple therapy, RAL (rabeprazole 20 mg, b.i.d., amoxicillin 1 g, b.i.d, levofloxacin 500 mg, once daily). The primary outcome was the eradication rate in the intention-to-treat (ITT) and per protocol (PP) analysis. Results: The eradication rates of the above 3 groups using ITT analysis were RBAL 83.8%, RBMT 88.3%, and RAL 74.8% compared with 91.2, 92.5, and 79.2%, respectively, using PP analysis. The eradication rate using RBMT was significantly higher than that of RAL (p = 0.029 in ITT analysis and p = 0.017 in PP analysis). Several side effects occurred in 156 patients (54.1%) in the RBAL group, 215 (52.3%) in the RBMT group, and 56 (26.2%) in the RAL group (p > 0.05, RBAL vs. RBMT; p < 0.001, RBMT vs. RAL; p < 0.001, RBAL vs. RAL). Conclusion: All bismuth-containing quadruple therapies had acceptable eradication rates, but levofloxacin-containing triple therapy was not as good as quadruple therapies. Hence, quadruple therapies should be considered the preferred first-line therapy for H. pylori infections. (C) 2017 The Author(s) Published by S. Karger AG, Basel
引用
下载
收藏
页码:523 / 529
页数:7
相关论文
共 50 条
  • [31] First-line triple therapy with levofloxacin for Helicobacter pylori eradication
    Gisbert, J. P.
    Fernandez Bermejo, M.
    Molina Infante, J.
    Perez Gallardo, B.
    Prieto Bermejo, A.
    Mateos Rodriguez, J.
    Robledo Andres, P.
    Gonzalez Garcia, G.
    HELICOBACTER, 2007, 12 (04) : 432 - 432
  • [32] First-line triple therapy with levofloxacin for Helicobacter pylori eradication
    Gisbert, J. P.
    Fernandez-Bermejo, M.
    Molina-Infante, J.
    Perez-Gallardo, B.
    Prieto-Bermejo, A.-B.
    Mateos-Rodriguez, J.-M.
    Robledo-Andres, P.
    Gonzalez-Garcia, G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (03) : 495 - 500
  • [33] Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection
    Federico, Alessandro
    Nardone, Gerardo
    Gravina, Antonietta G.
    Iovene, Maria Rosaria
    Miranda, Agnese
    Compare, Debora
    Pilloni, Paola A.
    Rocco, Alba
    Ricciardiello, Luigi
    Marmo, Riccardo
    Loguercio, Carmelina
    Romano, Marco
    GASTROENTEROLOGY, 2012, 143 (01) : 55 - U563
  • [34] The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication
    Arj, Abbas
    Mollaei, Marzieh
    Razavizadeh, Mohsen
    Moraveji, Alireza
    JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2020, 9 (02) : 101 - 105
  • [35] Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
    Yang, Jing
    Zhang, Yi
    Fan, Ling
    Zhu, Yang-Jie
    Wang, Ting-Yi
    Wang, Xing-Wei
    Chen, Dong-Feng
    Lan, Chun-Hui
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (03): : 437 - 445
  • [36] Second line bismuth-containing quadruple therapy for Helicobacter pylori eradication in Korea
    Cho, M.
    Hwang, H.
    Kim, Y.
    Lim, C.
    Oh, J.
    HELICOBACTER, 2019, 24
  • [37] Meta-Analysis: Lactobacillus Containing Quadruple Therapy Versus Standard Triple First-Line Therapy for Helicobacter pylori Eradication
    Zou, Jian
    Dong, Jie
    Yu, Xiaofeng
    HELICOBACTER, 2009, 14 (05) : 97 - 107
  • [38] Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial
    Romano, Marco
    Cuomo, Antonio
    Gravina, Antonietta G.
    Miranda, Agnese
    Iovene, Maria Rosaria
    Tiso, Angelo
    Sica, Mariano
    Rocco, Alba
    Salerno, Raffaele
    Marmo, Riccardo
    Federico, Alessandro
    Nardone, Gerardo
    GUT, 2010, 59 (11) : 1465 - 1470
  • [39] Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
    Zhan-Yue Niu
    Si-Zhu Li
    Yan-Yan Shi
    Yan Xue
    World Journal of Gastroenterology, 2021, 27 (25) : 3913 - 3924
  • [40] Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
    Niu, Zhan-Yue
    Li, Si-Zhu
    Shi, Yan-Yan
    Xue, Yan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (25) : 3913 - 3924